Join the club for FREE to access the whole archive and other member benefits.


University of Exeter spinout aiming to develop senotherapeutic interventions

SENISCA is a biotech spinout company from the University of Exeter, founded in 2020 and dedicated to the development of new approaches to reverse cellular senescence (senotherapeutics).

Our founders are world leaders in molecular and cellular biology and have patent-protected an innovation for the reversal of cellular senescence. This innovation works by restoring the ability of cells to ‘fine tune’ the expression of their genes to rejuvenate aged cells.

At SENISCA, we are using this knowledge, concerning how and why cells become senescent, to develop a new generation of interventions, to turn back the ageing clock in old cells and to target the diseases and aesthetic signs of ageing. SENISCA interventions are small molecule or oligonucleotide-based.


Professor Lorna Harries - CSO (and co-founder)

Visit website:

 Login to view link, or join the club to get full access to all resources and other benefits.

 Login to view link, or join the club to get full access to all resources and other benefits.

See also: Academia University of Exeter - UK university and member of the Russell Group of leading research-intensive UK universities

Mentioned in this Resource


Professor of Molecular Genetics at the University of Exeter.

People at SENISCA

Company Representative

Chief Executive Officer and Co-founder of SENISCA


Exeter's company SENISCA raises £2 million to treat age-related chronic diseases

University of Exeter - 09-Jun-2022

Funding might allow RNA-based rejuvenation tech to enter ex vivo lab tests


SENISCA to reverse senescence by targeting RNA splicing patterns

Longevity Technology - 08-Apr-2022

Lorna Harries details significant breakthroughs at fourth annual Longevity Leaders World Congress


SENISCA targets sensescence using a new ageing hallmark - dysregulated mRNA processing (LEAF) - 03-Nov-2021

Lorna Harries believes dysregulated splicing as a breakthrough senotherapeutic target


SENISCA secures 1.3 million pounds to transform anti-ageing technology

University of Exeter - 12-Mar-2021

Spin out company from University of Exeter step forward towards precision medicine for age-related diseases


LMC provides background and success outlook on 14 leading senolytic companies

Longevity Marketcap - 15-Dec-2020

Comprehensive review of companies' clinical and financial state of play


Nature Biotechnology reviews the state of play of senolytics

Nature Biotechnology - 12-Nov-2020

In August, Unity announced that its lead drug candidate had failed to beat a placebo in reducing ...


Taking the new path in the field of senolytics - SENISCA

Longevity Technology - 29-Jul-2020

Old cells will be more young and beautiful